

Invitation to the Extraordinary General Shareholders' Meeting 2022 of Epigenomics AG, Berlin

– ISIN: DE000A3H2184 / WKN: A3H218 –

Dear Shareholders,

We hereby invite you to attend

**the Extraordinary General Shareholders' Meeting of Epigenomics AG
on Friday, October 21, 2022, at 10:00 a.m. (CEST).**

The General Shareholders' Meeting will be held as a **virtual General Shareholders' Meeting without the physical presence of the shareholders** or their authorized representatives. The virtual General Shareholders' Meeting will be **broadcasted live with images and sound on the internet** for registered shareholders. The venue of the virtual General Shareholders' Meeting for purposes of the German Stock Corporation Act (*Aktiengesetz, AktG*) is Leopoldstraße 8, 80802 Munich, Germany.

PART A. AGENDA

1.

Notice by the Executive Board of the loss of half of the capital stock pursuant to Section 92 para. 1 AktG

The General Shareholders' Meeting is notified that the Company has suffered a loss amounting to half of its share capital.

No resolution of the General Shareholders' Meeting is planned for this item of the agenda, as it is limited according to statutory regulation to the notice by the Executive Board of the loss of half of the capital stock pursuant to Section 92 para. 1 AktG.

2.

Resolution on the reduction of the share capital by redemption of shares in a simplified form and amendment of the Articles of Association

In order to establish an even reduction ratio of 4 : 1 for the ordinary capital reduction proposed under agenda item no. 3, one shareholder has agreed to transfer three shares to the Company free of charge. Two of these shares are to be redeemed and the share capital will be reduced accordingly from EUR 16,357,482.00 by EUR 2.00 to EUR 16,357,480.00.

The Executive Board and the Supervisory Board propose to resolve:

- a) The Company's share capital in the amount of EUR 16,357,482.00, divided into 16,357,482 no-par value registered shares, is reduced by EUR 2.00 to

EUR 16,357,480.00 in simplified form pursuant to Section 237 para. 3 no. 1, para. 4 and para. 5 AktG by redemption of two shares acquired by the Company free of charge. The capital reduction by redemption shall be effected for the purpose of allocation to the capital reserves of the Company and to create an even reduction ratio of 4 : 1 for the ordinary capital reduction proposed under item no. 3 of the agenda. The proportionate amount of the share capital of EUR 2.00 attributable to the two shares to be redeemed shall be transferred to the Company's capital reserves.

- b) The Executive Board is authorized, with the consent of the Supervisory Board, to determine the further details concerning the reduction of the share capital and its implementation.
- c) Section 5 (1) and (2) of the Articles of Association are amended as follows:
 - "(1) The Company's share capital amounts to € 16,357,480.00 (in words: EURO sixteen million four hundred eighty).
 - (2) The share capital is divided up into 16,357,480 non-par value shares."

The proposed resolution is based on the Company's share capital as of the date of the invitation to the General Shareholders' Meeting. If the share capital increases because holders of convertible bonds issued by the Company exercise their conversion right during the conversion period at the beginning of October 2022 before the General Shareholders' Meeting the Executive Board and the Supervisory Board will submit a correspondingly amended proposal for a resolution. This amended proposal for a resolution will provide for a reduction of the share capital by means of redemption of shares in such amount that the share capital of the Company is reduced to the next lower amount that is evenly dividable by four (thus a maximum number of three shares in the aggregate amount of EUR 3.00 might be redeemed). The proposal for an amended resolution will also provide for accordingly adjusted figures for Section 5 (1) and (2) of the Articles of Association. If the share capital is evenly dividable by four at the time of the General Shareholders' Meeting, the Execution Board and the Management Board will not submit a proposal for a resolution for item no. 2 of the agenda and, as a result, not propose a capital reduction by means of redemption of shares.

3.

Resolution on the reduction of the share capital by way of an ordinary capital reduction through consolidation of shares for the purpose of offsetting losses and the allocation to the capital reserve of the Company as well as amendment of the Articles of Association

The Company's interim financial statements as of August 31, 2022 show losses totaling EUR 81,264,096.21 (losses carried forward totaling EUR 75,876,617.60 and net losses for the current fiscal year 2022 totaling EUR 5,387,478.61), with a capital reserve of EUR 72,489,216.37. The losses not covered by the capital reserve therefore amount to

EUR 8,774,879.84. Furthermore, since the beginning of November 2021, the Company's share price has been constantly below EUR 1.00. This limits the Company's ability to raise new funds quickly and flexibly, which is important for the Company. Against this background, the share capital shall be reduced for the purposes of covering losses to the extent that these exceed the capital reserve (*i.e.*, in the amount of EUR 8,774,879.84), and otherwise for the purposes of transferring them to the Company's capital reserve.

The Executive Board and the Supervisory Board therefore propose to resolve:

- a) The share capital reduced to EUR 16,357,480.00 in accordance with item no. 2 of the agenda, divided into 16,357,480 registered no-par value shares without nominal value, is reduced by EUR 12.268.110.00 to EUR 4,089,370.00. The reduction of the share capital is carried out as an ordinary capital reduction pursuant to Sections 222 et seq. AktG. In the amount of EUR 8,774,879.84 it serves the purpose of covering losses and otherwise the purpose of allocation to the Company's capital reserves.
- b) The reduction of the share capital will be carried out in such way that the 16,357,480 non-par value shares will be consolidated at a ratio of 4 : 1.
- c) The Executive Board is authorized, with the consent of the Supervisory Board, to determine the further details concerning the reduction of the share capital and its implementation.
- d) Section 5 (1) and (2) of the Articles of Association are amended as follows:
 - "(1) The Company's share capital amounts to € 4,089,370.00 (in words: EURO four million eighty-nine thousand three hundred seventy).
 - (2) The share capital is divided up into 4,089,370.00 non-par value share.

The Company's interim financial statements as of August 31, 2022 are available as of the time of convening of the virtual General Shareholder's Meeting on the Company's website at <https://www.epigenomics.com/news-investors/general-shareholder-meeting/>. There they will also be accessible during the virtual General Shareholder's Meeting.

The proposal for a resolution on item no. 3 of the agenda is also based on the Company's share capital as of the date of the invitation to the General Shareholders' Meeting. If the share capital increases because holders of convertible bonds issued by the Company exercise their conversion right during the conversion period at the beginning of October 2022 before the General Shareholders' Meeting the Executive Board and the Supervisory Board will submit a correspondingly amended proposal for a resolution. This amended proposal for a resolution will provide for a reduction of 75% of the then current and – in case a resolution is passed on item no. 2 of the agenda – correspondingly reduced share capital by means of consolidation of shares.

The proposal for an amended resolution will also provide for accordingly adjusted figures for Section 5 (1) and (2) of the Articles of Association.

PART B.
**FURTHER INFORMATION AND DETAILS ON THE EXTRAORDINARY GENERAL
SHAREHOLDERS' MEETING**

1. Conducting the Extraordinary General Shareholders' Meeting as a virtual General Shareholders' Meeting

On the basis of Section 118a AktG in conjunction with Section 26n para. 1 of the Introductory Act to the German Stock Corporation Act (*Einführungsgesetz zum Aktiengesetz*), each of which was last amended by the Act on the Introduction of virtual General Shareholders' Meetings of Stock Corporations and Amendment of Cooperative and Insolvency and Restructuring Law Provisions of July 20, 2022 (*Gesetz zur Einführung virtueller Hauptversammlungen von Aktiengesellschaften und Änderung genossenschafts- sowie insolvenz- und restrukturierungsrechtlicher Vorschriften vom 20. Juli 2022*; BGBl. I, p. 1166 et seq.), the General Shareholders' Meeting, with the consent of the Supervisory Board, will be held as a virtual General Shareholders' Meeting without the physical presence of the shareholders or their authorized representatives. This means:

- **No physical participation.** Physical participation by shareholders and their authorized representatives is excluded.
- **Broadcast on the Shareholders' Portal.** Instead, the virtual General Shareholders' Meeting will be broadcasted live with images and sound on the password-protected internet portal of the Company (Shareholders' Portal) on Friday, October 21, 2022 starting at 10:00 a.m. (CEST) at <https://www.epigenomics.com/news-investors/general-shareholder-meeting/>.
- **Access to the Shareholders' Portal.** To access the Shareholders' Portal, shareholders require their shareholder number and the related login password. The shareholder number and the login password are contained in the materials sent to the shareholders with the invitation to the virtual General Shareholders' Meeting; shareholders who are already registered in the Shareholders' Portal will also receive a new password. If shareholders do not receive the convening documents unsolicited - for example because they are not yet entered in the share register on the date relevant for sending the documents - they will be sent to the shareholders upon request. Such request must be sent to the registration address stated in section 2 below.
- **Registration requirement.** For the purposes of merely following the broadcast of the virtual General Shareholders' Meeting in the Shareholders' Portal as well as taking note of the Executive Board's report or its material content and questions answered in advance via the Shareholders' Portal access to the Shareholders' Portal is sufficient and no registration for the virtual General Shareholders'

Meeting is required. Shareholders who do not merely wish to follow the virtual General Shareholders' Meeting and to access the report of the Executive Board or its material content and the questions answered in advance, but wish to participate in the virtual General Shareholders' Meeting and, for example, exercise voting rights, submit statements, give speeches, ask questions or declare objections, must register for the virtual General Shareholders' Meeting latest on Friday, October 14, 2022, 24:00 hours (CEST) (see section 2 below).

- **Exercise of voting rights.** Shareholders may exercise their voting rights by electronic postal vote (see section 5 below). It is also possible to grant power of attorney to third parties, however, the granting of power of attorney to proxies appointed by the Company is not provided for. Authorized third parties also may not physically attend the virtual General Shareholders' Meeting; rather they may exercise the voting rights for the shareholders they represent by means of electronic postal vote (see section 6 below).
- **Motions and election proposals.** Shareholders electronically connected to the virtual General Shareholders' Meeting may submit motions and election proposals in the virtual General Shareholders' Meeting by means of video communication within the meaning of Section 118a para. 2 Sentence 2 no. 3 AktG (see section 7.2 below).
- **Report of the Executive Board.** The report of the Executive Board or its material content will be made accessible latest on Thursday, October 13, 2022, 24:00 hours (CEST) via the Shareholders' Portal.
- **Statements.** Shareholders properly registered for the virtual General Shareholders' Meeting may submit statements on the items on the agenda in text form via the Shareholders' Portal latest on Saturday, October 15, 2022, 24:00 hours (CEST). Properly submitted statements will be made accessible by the Company via the Shareholders' Portal to shareholders properly registered for the virtual General Shareholders' Meeting latest on Sunday, October 16, 2022, 24:00 hours (CEST) (see section 7.3 below).
- **Speeches.** Shareholders electronically connected to the virtual General Shareholders' Meeting are entitled to speak at the virtual General Shareholders' Meeting by means of video communication. The Company reserves the right to test the functionality of the video communication between the shareholder and the Company during the virtual General Shareholders' Meeting before the speech and to reject the speech if the functionality of the video communication is not ensured (see section 7.4 below).
- **Questions.** Shareholders properly registered for the virtual General Shareholders' Meeting have the right to request information from the Executive Board on matters relating to the Company via the Shareholders' Portal latest on Monday, October 17, 2022, 24:00 hours (CEST) insofar as the information is necessary for the proper assessment of an item on the agenda. Properly submitted

questions and the corresponding answers will be made accessible to the Shareholders latest on Wednesday, October 19, 2022, 24:00 hours (CEST) via the Shareholders' Portal. Shareholders electronically connected to the virtual General Shareholders' Meeting also have the right to ask follow-up questions in the virtual General Shareholders' Meeting to all responses given by the Executive Board prior to and during the virtual General Shareholders' Meeting, as well as questions on matters arising after expiry of October 17, 2022, meaning after Monday, October 17, 2022, 24:00 hours. It is planned that the chairman of the meeting will determine that such questions may be asked only by means of video communication (see section 7.5 below).

- ***Declaration of objections.*** Shareholders electronically connected to the virtual General Shareholders' Meeting can declare an objection to a resolution of the virtual General Shareholders' Meeting electronically (see section 8 below).

The live broadcast in the Shareholders' Portal and the participation rights in the virtual General Shareholders' Meeting do not permit physical or electronic participation in the virtual General Shareholders' Meeting within the meaning of Section 118 para. 1 Sentence 2 AktG.

2. Attendance at the virtual General Shareholders' Meeting

Shareholders who merely wish to follow the broadcast of the General Shareholders' Meeting and to take note of the Executive Board's report or its material content and questions answered in advance via the Shareholders' Portal do not need to register for the virtual General Shareholders' Meeting. Rather, access to the Shareholders' Portal is sufficient.

However, shareholders of the Company who do not merely wish to follow the broadcast of the virtual General Shareholders' Meeting and to take note of the Executive Board's report or its material content and questions answered in advance via the Shareholders' Portal, but intend to participate in the virtual General Shareholders' Meeting and, in particular, to exercise their voting rights will be entitled to do so only if they are entered as shareholders into the Company's share register and register with the Company to attend the virtual General Shareholders' Meeting.

The registration must be made in German or English and must be received by the Company latest by Friday, October 14, 2022, 24:00 hours (CEST).

In particular, the registration may be made via the internet using the password-protected Shareholders' Portal at <https://www.epigenomics.com/news-investors/general-shareholder-meeting/>. Shareholders gain online access by entering their shareholder number and the related access password.

If registration is not made using the Shareholders' Portal, registration in text form must be received by the Company in German or English

at the following address

Epigenomics AG
c/o Computershare Operations Center
80249 Munich

or by email to anmeldestelle@computershare.de.

Intermediaries may only exercise voting rights for shares which they do not own but for which they are entered in the Company's share register as the holder on the basis of an authorization from the owner of the shares. The same applies to persons and associations within the meaning of Section 135 para. 8 AktG, which include in particular shareholders' associations and proxy voting advisory firms.

3. Entering changes in the share register

As stated in section 2 above, only those shareholders who are entered in the share register and have properly registered in due time with the Company for the virtual General Shareholders' Meeting are authorized to participate in the virtual General Shareholders' Meeting and to exercise their voting rights. In this respect, entry in the share register at the time of the virtual General Shareholders' Meeting is the relevant point in time. In order to ensure proper preparation and conduct of the virtual General Shareholders' Meeting, the Company will not make any changes to the entries in the share register, *i.e.*, it will not perform any cancellations from or add new entries to the share register, if the request for a change of a register entry is received by the Company after the end of October 14, 2022, *i.e.*, after Friday, October 14, 2022, 24:00 hours (CEST). If a request for a change of a register entry is received by the Company after October 14, 2022, the entry in the share register will be changed after the virtual General Shareholders' Meeting has ended; the right to attend and vote at the virtual General Shareholders' Meeting pertaining to the shares affected by the change of the register entry will remain with the person whose name is to be canceled in the share register based on such request for a change of the register entry.

It is therefore recommended to file requests for changes of share register entries in good time before the date of the virtual General Shareholders' Meeting.

4. Holders of American Depositary Receipts (ADR)

Holders of American Depositary Receipts (ADR) can obtain further information from

Shareholder correspondence:
BNY Mellon Shareowner Services
P.O. Box 43006
Providence RI 02940-3078
USA

Overnight Correspondence:
BNY Mellon Shareowner Services
150 Royall St., Suite 101
Canton, MA 02021

USA

Tel. +1 888-269-2377 (toll-free number in the U.S.)

Tel. +1 201 680 6825 (international)

Website: www.mybnymdr.com

E-Mail: shrrelations@cpushareownerservices.com

5. Procedure for electronic absentee voting

Shareholders may cast their votes via electronic absentee voting (electronic postal vote). Shareholders must duly register in order to be able to exercise their voting rights.

Our internet-based Shareholders' Portal at <https://www.epigenomics.com/news-investors/general-shareholder-meeting/> is accessible for casting votes by electronic postal vote. Electronic postal voting via the internet-based Shareholders' Portal can take place until the closing of the voting by the chairman of the meeting in the virtual General Shareholders' Meeting. Shareholders and proxies are asked to exercise their voting rights as early as possible.

6. Authorizing third parties

Shareholders may exercise their voting rights in the virtual General Shareholders' Meeting also by authorized representatives, *e.g.* an intermediary, a shareholders' association, a proxy voting advisory firm or any other person of their choice, whereas granting power of attorney to a proxy nominated by the Company is not provided for. In the case of proxy voting, too, as stated in section 2 above, shareholders must be registered in the share register of the Company and must have registered themselves or their authorized representatives for the virtual General Shareholders' Meeting in due time.

Authorized representatives cannot physically participate in the virtual General Shareholders' Meeting. They may exercise voting rights for the shareholders whom they represent by way of by electronic absentee voting only, as described in section 5 above.

The granting and revocation of power of attorney and proof of authorization of third parties towards the Company must be in text form. Where power of attorney is granted to intermediaries or any persons and associations pursuant to Section 135 para. 8 AktG (which include in particular shareholders' associations and proxy voting advisory firms), the provisions of Section 135 AktG must be observed. Section 135 AktG provides in particular that the authorized representative must keep a verifiable record of the power of attorney granted to it. Furthermore, the power of attorney must be complete and may only contain declarations relating to the exercise of voting rights. In addition, any rules that are relevant to the authorized representative with respect to its authorization must be observed and should be clarified with the authorized representative.

The granting of power of attorney vis-à-vis the Company and the transmission to the Company of the proof of power of attorney granted to the authorized representative and of a possible revocation thereof, may be effected in text form as of Thursday, October 20, 2022, 24:00 hours (CEST) at the latest,

to the following address

Epigenomics AG
c/o Computershare Operations Center
80249 Munich

or by email to anmeldestelle@computershare.de.

Forms for granting power of attorney and giving instructions are sent to the shareholders together with the invitation.

In addition, the granting of power of attorney vis-à-vis the Company may be done via the Shareholders' Portal under <https://www.epigenomics.com/news-investors/general-shareholder-meeting/> until the end of the virtual General Shareholders' Meeting.

The participation of the authorized representative via the Shareholders' Portal requires that the authorized representative has the information required for access. The authorized representative may obtain the information in three ways. First, the shareholder can, when authorizing his representative via the Shareholders' Portal, enter an e-mail address to which the login-in data for the representative are sent. Secondly, the login-in data are sent via post to the address stated when authorizing the representative if the representative is not authorized via the Shareholders' Portal but in text form. If no post address is provided in connection with the authorization the login-in data for the representative are sent to the shareholder. In order to ensure timely receipt of the access password, shareholders are requested to issue the authorization early. Thirdly, the representative can use the shareholders' login in if the shareholder provides his representative with his shareholder number and access password. Unlike the first two options, the representative does in this case not use his own login-in data but the login-in data of the shareholder which grant the representative access to all personal data relating to the shareholder stored in the Shareholders' Portal. The use of the shareholder number and access password of the shareholder by the authorized representative also serves as proof of authorization vis-à-vis the Company.

7. Rights of shareholders

7.1 Request to include items on the agenda pursuant to Section 122 para. 2 AktG

Shareholders whose shares in the aggregate amount to no less than one twentieth of the share capital or represent a proportional amount of no less than EUR 500,000.00 may request that items be included on the agenda and be published. Each new item must be accompanied by an explanation or a proposal for a resolution. Any such request must be received in writing by the Company by the end of September 20,

2022, *i.e.*, by Tuesday, September 20, 2022, 24:00 hours (CEST). The request must be addressed in writing to the Executive Board of Epigenomics AG. Please address any such request exclusively to:

Epigenomics AG
Executive Board
Attn.: Jens Ravens
Geneststraße 5
10829 Berlin

Additions to the agenda that are to be published will be published in the German Federal Gazette (*Bundesanzeiger*) without undue delay after receipt of the request unless they have already been published together with the invitation to the General Shareholders' Meeting. In addition, these requests will be made accessible on the internet at <https://www.epigenomics.com/news-investors/general-shareholder-meeting/> and communicated in accordance with Section 125 AktG.

Shareholders requesting to have an item added to the agenda must provide proof that they have held the shares for at least 90 days prior to the day of receipt of the request by the Company and that they will hold the shares until the request has been decided upon by the Executive Board. Section 70 AktG applies to the calculation of the shareholding period. In all other respects, Section 121 para. 7 AktG applies *mutatis mutandis* when calculating the time limit. Accordingly, the day on which the request is received by the Company is not to be counted. Any postponement from a Sunday, Saturday or public holiday to a preceding or subsequent working day is not possible. Sections 187 to 193 of the German Civil Code (*Bürgerliches Gesetzbuch, BGB*) do not apply *mutatis mutandis*.

7.2 Counter-motions and election proposals of shareholders pursuant to Sections 126, 127, 130a para. 5 Sentence 3, 118a para. 1 Sentence 2 no. 3 AktG

Every shareholder is entitled to make counter-motions against the proposals made by the Executive Board and/or the Supervisory Board with respect to certain items on the agenda and election proposals even before the virtual General Shareholders' Meeting. Such counter-motions and proposals for election by shareholders, including the name of the shareholder, are to be made accessible by the Company pursuant to Sections 126, 127 AktG if they are received by the Company

to the following address

Epigenomics AG
Geneststraße 5
10829 Berlin

or by email to HV@epigenomics.com

by the end of October 6, 2022, *i.e.*, by Thursday, October 6, 2022, 24:00 hours (CEST), at the latest, and comply with the statutory requirements in all other respects.

In addition, Sections 126 para. 2, 127 Sentences 1 and 3 AktG govern the preconditions for not having to make counter-motions and election proposals accessible. Counter-motions and election proposals will be made accessible in compliance with the statutory provisions on the Company's website at <https://www.epigenomics.com/news-investors/general-shareholder-meeting/>. Any comments by the management on received counter-motions and election proposals will likewise be published under the internet address stated above.

Pursuant to Section 126 para. 4 AktG, counter-motions and voting proposals of shareholders that are to be made accessible by the Company shall be deemed to have been made at the time they are made accessible. If the shareholder who has submitted the motion is not entered as a shareholder in the Company's share register at the time of the virtual General Shareholders' Meeting or has not registered for the virtual General Shareholders' Meeting, the motion need not be dealt with in the virtual General Shareholders' Meeting. The Company will ensure that shareholders properly registered for the virtual General Shareholders' Meeting can exercise their voting rights on appropriately submitted counter-motions and voting proposals once they are made accessible on the Company's internet site.

Counter-motions and voting proposals as well as other motions may also be made during the virtual General Shareholders' Meeting by means of video communication. Video communication takes place via the internet-based Shareholders' Portal at <https://www.epigenomics.com/news-investors/general-shareholder-meeting/>.

Pursuant to Section 130a para. 6 AktG, the Company reserves the right to test the functionality of the video communication between the shareholder and the Company in the virtual General Shareholders' Meeting and prior to the shareholder's speech and to reject it if the functionality is not ensured.

7.3 Right to submit statements pursuant to Section 130a para. 1 through 4 and para. 6 AktG

Shareholders properly registered for the virtual General Shareholders' Meeting have the right to submit statements on the agenda items by the end of October 15, 2022, *i.e.* by Saturday, October 15, 2022, 24:00 hours (CEST).

Submissions must be made in text form as a pdf file on the Shareholders' Portal at <https://www.epigenomics.com/news-investors/general-shareholder-meeting/>.

Statements must not exceed 20,000 characters (including spaces).

The Company will make the statements accessible to all shareholders properly registered for the virtual General Shareholders' Meeting by the end of October 16, 2022, *i.e.* by Sunday, October 16, 2022, 24:00 hours (CEST). They will be made accessible via the Shareholders' Portal at <https://www.epigenomics.com/news-investors/general-shareholder-meeting/>. Statements will not be made accessible if they do not stem from a shareholder appropriately registered for the virtual General Shareholders' Meeting, if they exceed 20,000 characters (including spaces), or if a case

within the meaning of Section 130a para. 3 Sentence 4, in conjunction with Section 126 para. 2 Sentence 1 no. 1, no. 3 or no. 6 AktG exists.

Section 131 para. 1d AktG does not apply to statements submitted in advance. Any questions contained in statements will therefore not be answered in the virtual General Shareholders' Meeting unless they are asked within the exercise of the right to ask questions (see section 7.5 below).

When making statements accessible, the Company will disclose the names of the statements' authors only if they have expressly requested or expressly consented to a disclosure when submitting the questions.

7.4 Right to speak pursuant to Section 130a para. 5 and para. 6 AktG

Shareholders electronically connected to the virtual General Shareholders' Meeting (*i.e.* via the Shareholders' Portal) and their authorized representatives have the right to speak at the virtual General Shareholders' Meeting. The right to speak is exercised by means of video communication. Motions and voting proposals pursuant to Section 118a para. 1 Sentence 2 no. 3 AktG, follow-up questions pursuant to Section 131 para. 1d AktG, and questions pursuant to Section 131 para. 1e AktG may form part of the speech.

Video communication takes place via the internet-based Shareholders' Portal at <https://www.epigenomics.com/news-investors/general-shareholder-meeting/>.

Pursuant to Section 130a para. 6 AktG, the Company reserves the right to test the functionality of the video communication between the shareholder and the Company in the virtual General Shareholders' Meeting and prior to the shareholder's speech and to reject it if the functionality is not ensured.

7.5 Right to ask questions pursuant to Section 131 AktG

Right to ask questions before the virtual General Shareholders' Meeting

Shareholders properly registered for the virtual General Shareholders' Meeting may request information on the Company's affairs until the end of October 17, 2022, *i.e.* by Monday, October 17, 2022, 24:00 hours (CEST), insofar as the information is necessary for the proper assessment of an item on the agenda. The Company's duty to provide information also extends to the legal and business relations of the Company with an affiliated company as well as the state of the group and the companies included in the consolidated financial statements.

Questions from shareholders must be in text form and must be received by the Company via the Shareholders' Portal at <https://www.epigenomics.com/news-investors/general-shareholder-meeting/>. Any other method of transfer is excluded. Each questions asked before the General Shareholders' Meeting is limited to 5,000 characters (including spaces).

With regard to the (partial) advanced timing of the right to ask questions and the opportunity to submit statements in advance (above under section 7.3), the Company

will make the report of the Executive Board or its material content accessible to shareholders via the Shareholders' Portal by the end of October 13, 2022, i.e. by Thursday, October 13, 2022, 24:00 hours (CEST).

The Company will answer all properly submitted questions by the end of October 19, 2022, i.e. by Wednesday, October 19, 2022, 24:00 hours (CEST), and make the questions and corresponding answers accessible to the shareholders. Questions will not be made accessible if they do not stem from a shareholder appropriately registered for the virtual General Shareholders' Meeting or if a case within the meaning of Section 131 para. 1c Sentence 3, in conjunction with Section 126 para. 2 Sentence 1 no. 1, no. 3 or no. 6 AktG exists.

Follow-up questions and questions on new matters within the meaning of Section 131 para. 1e AktG during the virtual General Shareholders' Meeting

Shareholders and their authorized representatives electronically connected to the virtual General Shareholders' Meeting, i.e. via the Shareholders' Portal, may ask follow-up questions during the virtual General Shareholders' Meeting about all answers provided by the Executive Board before and during the virtual General Shareholders' Meeting. Furthermore, during the virtual General Shareholders' Meeting they may ask questions on matters which arose after the deadline for exercising the right to ask questions before the virtual General Shareholders' Meeting, i.e. after the end of Monday, October 17, 2022. Such questions may also be asked as part of a speech (see section. 7.4 above).

It is planned that the chairman of the General Shareholders' Meeting will determine that such questions may be asked only by means of video communication. In this case and pursuant to Section 130a para. 6 AktG, the Company reserves the right to test the functionality of the video communication between the shareholder and the Company in the virtual General Shareholders' Meeting prior to the shareholder's speech and to reject it if the functionality is not ensured.

When answering questions and making them accessible prior to the virtual General Shareholders' Meeting, the Company will disclose the names of the questions' authors only if they have expressly requested or expressly consented to a disclosure when submitting the questions.

If a shareholder electronically connected to the virtual General Shareholders' Meeting is refused information, this shareholder may request via email to the email address notar-hauptversammlung-2022@epigenomics.com that their question and the reason given for why the information was refused are recorded in the minutes of the virtual General Shareholders' Meeting.

7.6 Further explanations

Additional explanations regarding shareholders' rights pursuant to Section 122 para. 2 AktG; Sections 126, 127, 130a para. 5 Sentence 3, 118a para. 1 Sentence 2 No 3 AktG; Section 130a para. 1 through 4 and para. 6 AktG; Section 130a para. 5 and

para. 6 AktG; as well as Section 131 AktG can be found on the website of Epigenomics AG at <https://www.epigenomics.com/news-investors/general-shareholder-meeting/>.

8. Objections to resolutions of the virtual General Shareholders' Meeting

Shareholders electronically connected to the virtual General Shareholders' Meeting are entitled to object to resolutions of the virtual General Shareholders' Meeting. Objections may be raised by sending an email to notar-hauptversammlung-2022@epigenomics.com once the virtual General Shareholders' Meeting has commenced and until its end. The objection must contain the name and shareholder number of the shareholder as proof of share ownership.

9. Total number of shares and voting rights at the time of convocation

As at the date of convening the General Shareholders' Meeting, the Company's share capital amounts to EUR 16,357,482.00 divided into 16,357,482 registered non-par value shares. Pursuant to § 18 (1) of the Articles of Association, each share entitles to one vote in the virtual General Shareholders' Meeting. Accordingly, as at the date of convening this virtual General Shareholders' Meeting, the total number of voting rights amounts to 16,357,482. The Company does not hold any treasury shares. After the date of publication of this invitation but before the beginning of the virtual General Shareholders' Meeting there is a conversion period for convertible bonds, issued by the Company, so that the share capital, shares and voting rights may increase by the time of the virtual General Shareholders' Meeting.

10. Reference to the Company's internet site

This invitation to the virtual General Shareholders' Meeting, any documents with respect to the items on the agenda, the other documents pursuant to Section 124a AktG as well as further information relating to the virtual General Shareholders' Meeting can be downloaded from the website <https://www.epigenomics.com/news-investors/general-shareholder-meeting/> as of the date on which the virtual General Shareholders' Meeting is convened.

The documents that are required to be made available to the virtual General Shareholders' Meeting will also be available during the virtual General Shareholders' Meeting on Friday, October 21, 2022 on the above-mentioned website.

11. Information on data protection for shareholders

As data controller, Epigenomics AG processes personal data relating to the shareholders (*e.g.*, surname and first name, address, email address, number of shares, type of share, type of share ownership and shareholder number) and, if applicable, personal data relating to shareholder representatives on the basis of the applicable data protection laws. The Company is required to maintain a share register.

The processing of personal data of shareholders and shareholder representatives is mandatory under applicable law for the proper preparation and conduct of the virtual General Shareholders' Meeting, for the exercise of shareholders' voting rights, for the

tracking of electronic participation and for the maintenance of the share register. The processing is based in legal terms on Sections 67, 67e AktG and point (c) of Article 6 para. 1 Sentence 1 GDPR in conjunction with Section 118 AktG. In addition, personal data that is necessary for the organization of the virtual General Shareholder's Meeting can be processed on the basis of prevailing legitimate interests (Article 6 para. 1 Sentence 1 lit. f) GDPR). Insofar as shareholders do not provide their personal data themselves, the Company will generally obtain these via the registration office and, if applicable, from the last intermediary that held the shares in custody on behalf of the relevant shareholder.

The service providers commissioned by Epigenomics AG for the purpose of organizing the virtual General Shareholders' Meeting will process the personal data of the shareholders and shareholder representatives exclusively in accordance with the instructions of the Company and only to the extent that this is necessary for the performance of the commissioned service. All employees of the Company and the employees of the commissioned service providers who have access to and/or process the personal data of the shareholders or shareholder representatives are obliged to treat this data confidentially. In addition, personal data of shareholders and shareholder representatives exercising their voting rights will be made available to other shareholders and shareholder representatives subject to the statutory requirements (in particular the list of participants, Section 129 AktG). This also applies to questions that shareholders or shareholder representatives have submitted and in connection with the announcement of a shareholder's request to include additional items on the agenda, and of counter-motions and election proposals.

The Company will erase the personal data of the shareholders and shareholder representatives in accordance with the statutory provisions, in particular if the personal data are no longer necessary for the original purposes of collection or processing, if the data are no longer required in connection with any administrative or court proceedings and if no statutory record retention requirements apply.

Subject to the statutory requirements, shareholders and shareholder representatives have the right to receive information about their processed personal data and to request the rectification or erasure of their personal data or the restriction of the processing thereof. In addition, the shareholders or shareholder representatives, as the case may be, have the right to lodge a complaint with the supervisory authorities. If personal data are processed on the basis of Article 6 para. 1 Sentence 1 lit. f) GDPR, shareholders or shareholder representatives, as the case may be, also have a right of objection subject to the statutory requirements.

For comments and queries regarding the processing of personal data, shareholders can contact the data protection officer of the Company: Dr. Uwe Schläger, datenschutz nord GmbH, Niederlassung Berlin, Reinhardtstr. 46, 10117 Berlin; email: office@datenschutz-nord.de; phone: +49 30 30877490.

Convenience Translation – For information purposes only
The German version alone is relevant and authoritative

Additional information on data protection is available for shareholders on the Company's website at <https://www.epigenomics.com/imprint/data-protection-statement/>.

Berlin, in September 2022

Epigenomics AG
The Executive Board